Contrasting Proteome Biology and Functional Heterogeneity of the 20 S Proteasome Complexes in Mammalian Tissues*

Aldrin V. Gomes‡, Glen W. Young‡, Yueju Wang, Chenggong Zong, Mansoureh Eghbali, Oliver Drews, Haojie Lu, Enrico Stefani, and Peipei Ping§

The 20 S proteasome complexes are major contributors to the intracellular protein degradation machinery in mammalian cells. Systematic administration of proteasome inhibitors to combat disease (e.g. cancer) has resulted in positive outcomes as well as adversary effects. The latter was attributed to, at least in part, a lack of understanding in the organ-specific responses to inhibitors and the potential diversity of proteomes of these complexes in different tissues. Accordingly, we conducted a proteomic study to characterize the 20 S proteasome complexes and their postulated organ-specific responses in the heart and liver. The cardiac and hepatic 20 S proteasomes were isolated from the same mouse strain with identical genetic background.

We examined the molecular composition, complex assembly, post-translational modifications and associating partners of these proteasome complexes. Our results revealed an organ-specific molecular organization of the 20 S proteasomes with distinguished patterns of post-translational modifications as well as unique complex assembly characteristics. Furthermore, the proteome diversities are concomitant with a functional heterogeneity of the proteolytic patterns exhibited by these two organs. In particular, the heart and liver displayed distinct activity profiles to two proteasome inhibitors, epoxomicin and Z-Pro-Nle-Asp-H.

Finally, the heart and liver demonstrated contrasting regulatory mechanisms from the associating partners of these proteasomes. The functional heterogeneity of the mammalian 20 S proteasome complexes underscores the concept of divergent proteomes among organs in the context of an identical genome. Molecular & Cellular Proteomics 8: 302–315, 2009.

The proteasomes are enzymatic multi-protein complexes that are central to the ubiquitin-proteasome system. Proteasome complexes are found in diverse organisms and exist in all mammalian cell types. Multiple investigations document a defective ubiquitin-proteasome system in many human diseases. The reported pathogeneses are diverse, and the disease phenotypes are steadily increasing, with most investigative efforts being focused on the involvement of proteasomes in cancer. Inhibition of proteasomes has been found to be significantly beneficial for treating multiple myelomas and other forms of oncogenesis (1). However, recent reports documented dramatic side effects of proteasome inhibitors on other organs, particularly the heart (2–4), whereas the underlying mechanism is not understood. We postulate that tissue heterogeneity of proteasome structure and function exists, which may contribute to the dichotomous responses observed in different organs.

The proteolytic activities of the proteasome emanate from the core enzymes of the 20 S complexes. The 20 S proteasome is important for degrading oxidized proteins and has also been shown to degrade non-oxidized and non-ubiquitinated substrates, such as ornithine decarboxylase, p53 and p73 (5, 6). Every 20 S proteasome is composed of four stacked rings, with the inner rings containing seven β subunits (forming the central catalytic chamber) and the outer rings containing seven α subunits. Three of the β subunits (β1, β2, β5) are post-translationally cleaved at their amino terminus yielding active proteases (7). These three proteolytically active β subunits (β1, β2, β5) can be replaced with inducible counterparts (β1i, β2i, β5i) (8). The introduction of inducible subunits into 20 S proteasomes provokes a change in complex assembly, altering their proteolytic substrate specificity. A variable molecular organization of the 20 S complexes provides the cell with a dynamic range of proteolytic capacities and affords the potential for functional heterogeneities (9–11).

In this investigation, we examined the molecular composition, complex assembly, and post-translational modifications of the cardiac and the hepatic 20 S proteasomes from the same animal strain. Furthermore, we evaluated the functional impact of the diverse 20 S proteome biology in two different organs. Using blue-native polyacrylamide gel electrophoresis (BN-PAGE)† and subsequent LC-MS/MS analyses, we delin-

---

From the Departments of Physiology and Medicine, Cardiac Proteomics and Signaling Laboratory at Cardiovascular Research Laboratory, University of California, Los Angeles, School of Medicine, Los Angeles, California 90095

Received, February 5, 2008, and in revised form, October 1, 2008
Published, MCP Paper in Press, October 17, 2008, DOI 10.1074/mcp.M800058-MCP200

The abbreviations used are: BN-PAGE, blue-native polyacrylamide gel electrophoresis; DTT, dithiothreitol; PBS, phosphate-buffered saline; PPI, protein proximity index; CC, correlation coefficients; PKA, protein kinase A; PP2A, protein phosphatase 2A; CKII, casein kinase II; PP1, protein phosphatase 1; LC-MS/MS, liquid chromatography tandem mass spectrometry; E1, ubiquitin-activating enzyme; E2, ubiquitin carrier protein; E3, ubiquitin-protein isopeptide ligase; AMC, 7-amino-4-methyl coumarin.

† The paper is available on line at http://www.mcponline.org

© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
eated the molecular organization of the native 20 S protea-
some complexes and their associating partners. This is the
first proteomic report regarding organ-specific responses to
proteasome inhibition. Our data demonstrated significant het-
erogeneity in the proteome biology and proteolytic function of
the 20 S proteasome complexes in these organs.

MATERIALS AND METHODS

20 S Proteasome Purification—The 20 S proteasome complexes
were purified from the heart and liver of ICR mice, using a previously
described method (10). Briefly 10 g of tissue (heart or liver) was
homogenized by a polytron homogenizer in homogenizing buffer (20
mM Tris-HCl, pH 7.8, 0.1 mM EDTA, 1 mM DTT, protease inhibitor
mixture from Roche, and phosphatase inhibitor mixture from Sigma).
The homogenate was centrifuged for 2 h at 25,000 g to remove the
nuclear and mitochondrial fractions. The resulting supernatant (cyto-
solic fraction) was then precipitated with ammonium sulfate and the
pellet between 40% to 60% ammonium sulfate saturation was col-
lected and resuspended in 10 ml of dialysis buffer (20 mM Tris-HCI,
pH 7.4, 5 mM MgCl2, 0.5 mM DTT, glycerol 10%; buffer B: 20 mM Tris-HCI,
pH 7.4, 5 mM MgCl2, 0.5 mM DTT, glycerol 10%; buffer B:
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, protease inhibitor
mixture from GE Healthcare) by stepwise salt elution (200 ml of 45% buffer B; then 200 ml
of 75% buffer B, and finally 200 ml of 100% buffer B). Buffer A: 20
mM Tris-HCI, pH 7.4, 5 mM MgCl2, 0.5 mM DTT, glycerol 10%; buffer
B: 20 mM Tris-HCI, pH 7.4, 5 mM MgCl2, 0.5 mM DTT, glycerol 10%; 600 mM KCl), Enriched 20 S proteasomes were recovered from the
75% buffer B elution peak and centrifuged for 19 h at 42,000 rpm
(4 °C; Ti-45 fixed angle rotor from Beckman). The pellet was collected
and further resolved by another strong ion-exchange column (MonoQ
GL5/50 from GE Healthcare) by gradient elution of 17.5 column
volumes. The purified 20 S proteasomes were recovered at ~60% buffer B.

BN-PAGE—For separation of the purified 20 S proteasomes by
BN-PAGE, 1–3 μg of purified proteasome sample (at a concentration
of 1 μg/μl) was mixed with BN sample buffer (15 μl). BN-gels were
prepared as described previously (12). Briefly, 6% gels were cast in a
Bio-Rad Protean II minigel system. Ferritin (440 and 880 kDa; Sigma-Aldrich) was used as the molecular weight marker. The
buffers were 50 mM bis-Tris, pH 7.0 for the anode and 50 mM tricine,
15 mM bis-Tris, 0.02% Coomassie G250 for the cathode. Protein
samples were adjusted with a concentrated BN sample buffer to a
final concentration of 75 mM aminohexanoic acid, 5 mM bis-Tris,
and 0.05% Coomassie G250. For sample migration through the
stacking and the resolving gel, voltages were set to 100 and 500 V,
respectively. After one-third of the run time, the Coomassie-stained
cathode buffer was replaced with buffer containing 0.002% Coom-
assie G250.

Antibodies, Immunoblot Analysis, and Confocal Immunohisto-
chemistry—Immune complexes were detected using an Odyssey sys-
tem (LI-COR). Purified 20 S proteasomes were investigated by immu-
noblotting using 20 S antibodies (α3 (PW8115), α7 (PW8110), β1
(PW8140), β2 (PW9300), β5 (PW8895), β11 (PW8345), β21 (PW8350),
β5i (PW8200), anti-polylubiquitin (UG9510), anti-Σumu-1 (PW9480),
anti-core (PW8155), anti-Rpt4 (PW8830), and anti-NEED8 (PW9340)
from Biornol and anti-methylarginine (7E6A, Abcam), anti-methyllysine
(ab23366, Abcam), anti-glutathione (MAB5310; Chemicon) and acetyl
lysine (05–515) from Upstate. Phosphorylated proteins were detected
using an antibody mixture from Calbiochem, providing a more com-
plete profile of phosphoamino acid epitopes: anti-phosphoserine anti-
obodies 1C8, 4A3, 4A9, and 16B4 were combined and used to
detect phosphorylated serine residues, whereas anti-phosphothreo-
nine antibodies 1E11, 4D11, and 14B3 and anti-phosphotyrosine antibodies 3B12, 2CB, 16F4, and 9H8 were combined and used for
phosphorylated threonine or tyrosine residues, respectively. Protein
loading was controlled by Ponceau S staining of transblots before
immunoblotting and is representative of at least three replicates (n = 3).

Freshly isolated adult cardiomyocytes were isolated as described
previously (13, 14) and were plated on polylysine precoated covers-
slips (1 h at room temperature). The cells were then fixed in cold
acetone (10 min at −20 °C) or in 4% paraformaldehyde (20 min at
room temperature). Non-specific binding was blocked using 10% goat
or donkey serum, 0.2% Triton X-100 in phosphate-buffered saline
(PBS), pH 7.4 for 30 min at room temperature. The cells were incu-
ばted overnight at 4 °C with the primary antibody in 1% goat or
donkey serum, 0.2% Triton X-100 in PBS. Primary antibodies were:
anti-PP1 (1:300 dilution, sc-6108; Santa Cruz Biotechnology); anti-
CTK (1:100 dilution, 610444; BD Biosciences); anti-NEDD8 (1:100
dilution, ab50280; Abcam); anti-ZFHX4 (1:100 dilution, H00079776-
A01; Novus Biologicals); and anti-ξ3 (1:300 dilution; Invitrogen). Pri-
mary antibodies were washed with PBS (3 ×), and the cells were
incubated with Alexa 488 anti-rabbit IgG (2 μg/ml) and either Alexa
568 anti-mouse IgG1 (2 μg/ml) or Alexa 568 donkey anti-goat sec-
tary antibodies (Molecular Probes) in 1% goat or donkey serum,
0.2% Triton X-100 in PBS for 1 h at room temperature. The secondary
antibodies were washed with PBS (3 ×), and the cells were mounted
using ProLong anti-fade mounting medium (Invitrogen). Single
confocal acquisitions were acquired with a laser scanning confocal micro-
scope (60X, 1.4 NA, oil immersion) at −0.050 μm per pixel (Olympus
FluoView or high resolution confocal built in-house). To improve spa-
tial resolution, images were three-dimensional-blind deconvolved
(AutoQuant Imaging Inc.). The degree of association between two
proteins is measured via the protein proximity index (PPI) and corre-
lation coefficients (CC), calculated using the recently published algo-
rithms (15). The confocal data are representative images of four
different mice preparations and 8–10 cells per preparation.

Proteasome Immunoprecipitation—Purified 20 S proteasomes in
Nonidet P-40 immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, protease inhibitor
mixture from GE Healthcare) were incubated with rabbit anti-α3 an-
tibody (2 μg antibody per 5 mg protein) and 10 μl of protein A/G-
Sepharose resin (Santa Cruz Biotechnology) overnight at 4 °C. Sam-
ple were centrifuged at 1,000 × g for 2 min at 4 °C. The pellets were
washed three times in Nonidet P-40 immunoprecipitation buffer
and two times in PBS. Immunoprecipitated complexes were collected
by centrifugation at 3,000 × g for 2 min at 4 °C. After removing
the supernatant the proteasome-bound protein A/G beads were incu-
bated in SDS-PAGE buffer for 5 min at 95 °C and then run on 12%
SDS-PAGE gels. Gels were digested with trypsin and subsequently
analyzed by LC-MS/MS.

20 S Proteasome Activity Assay—The 20 S proteolytic activity
assay was carried out in a total volume of 100 μl in 96-well opaque
plates. The final composition of the 20 S assay buffer for the β5
proteasome activity was 25 mM HEPES, 0.5 mM EDTA, and 0.03% SDS
(pH 7.5). Assays were initiated by addition of 10 μl of a 10×
solution (250–5000 μM) of LLVY-AMC. The final composition of the
20 S assay buffer for the β1 and β2 proteasome activity were 25 mM
HEPES, 0.5 mM EDTA, 0.05% Nonidet P-40, and 0.001% SDS
(pH 7.5). Assays were initiated by addition of 10 μl of a 10× solution
(250–5000 μM) of LLE-AMC (β1) or LSTR-AMC (β2). Released AMC
was measured using a Fluoroskan Ascent fluorometer (Thermo Fisher
Scientific) at excitation wavelength 390 nm and emission wavelength
460 nm. Each well contained 0.065 μg of purified 20 S proteasome.
Fluorescence was measured at 15 min intervals for 2 h. All assays
were linear in this range, and each sample was assayed in quadruplicate. A standard curve was generated using different concentrations of free AMC that was added to protein-free wells. Proteasome activity results were expressed as means ± S.E. For measuring proteasome activities in cytosolic fractions (1 h at 100,000 × g supernatants), controls were carried out using specific proteasome inhibitor epoxomicin or Z-Pro-Nle-Asp-H. Each well contained 25 μg of cytosolic fraction, and assays were carried out as described above for the purified proteasomes.

Activity assays were performed on purified heart or liver 20 S proteasomes incubated with 10 nm Calyculin A (PP1 inhibitor; Upstate) for 10 min or 100 nm DMAT (CKII inhibitor) for 20 min and measured for all three proteasome proteolytic activities 30 min after the addition of substrate. For the recombinant studies, 36 nm recombinant PP1 (NEB) or 15 units of CKII was added to purified proteasomes with proteolytic activity measured 30 min after the addition of β1, β2, or β5 substrates. Proteasomes incubated with recombinant PP1 or CKII inactivated by heating at 60 °C for 1 h were used as controls. Data are averages of at least three independent experiments, * p < 0.05 for β5 cardiac activity with both recombinant PP1 compared with heat-inactivated recombinant PP1 and with inhibited PP1 compared with uninhibited activity. ** p < 0.05 for all three hepatic activities with recombinant CKII compared with the heat-inactivated recombinant CKII and inhibited CKII when compared with uninhibited activities.

Protein Identification by LC-MS/MS—Protein concentrations were determined using the Bio-Rad Protein Assay Reagent, and protein samples were loaded at equal amounts and run with either two-dimensional electrophoresis (GE Healthcare) or BN-PAGE (as discussed above). Stained proteins and unstained regions within the vicinity (served as background control) were excised, reduced, and alkylated (16). After tryptic digestion, recovered peptide mixtures underwent LC-MS/MS analysis on an LTQ-MS instrument (Thermo Fisher Scientific, San Jose, CA) with a Surveyor pump system using a reversed phase column (75 μm, inner diameter, 10 cm; BioBasic C18, 5-μm particle size; New Objective, Woburn, MA). The flow rate was 5 μl/min for sample loading and 250 nl/min for separation. Mobile phase A was 0.1% formic acid, 2% acetonitrile in water, and mobile phase B was 0.1% formic acid, 20% water in acetonitrile. A shallow gradient was used for analyses: linear gradient from 5% B to 40% B over 70 min, then to 100% B over 20 min, and finally a constant 100% B for 9 min. The ion transfer tube of the linear ion trap was held at 200 °C; the normalized collision energy was 35% for MS2; and the spray voltage was set at 1.9 kV.

Survey full-scan MS spectra with 1 microscan (m/z 400–2000) were acquired, followed by five sequential scan events of MS2. Each MS2 acquisition was operated under the data-dependent acquisition mode to automatically select ions with the top five highest intensities from the survey scan, with a 3.0 m/z isolation width. During acquisition, dynamic exclusion was enabled with 2 repeat counts within 10.0 s and with exclusion duration of 40.0 s. For 18O labeling, the data were acquired similarly in a data-dependent mode with 1 full MS scan followed by MS2 collision-induced dissociation and zoom scans on the top five most intense precursor ions. The zoom scan mass width was set at ±5 m/z.

MS/MS Spectra were searched against the international protein index mouse data base version 3.24 (which contains 52,326 proteins) with SEQUEST search engine (Bioworks 3.3). Fixed modifications were set for carbamidomethylation of cysteine. Differential modification was set for oxidation of methionine, as well as arginine and lysine mono- and di-methylated and allowing for one missed trypptic cleavage. Filter criteria were set to pass a significant threshold of cross-correlation versus charge state (2 for −1 ions, 2.2 for +2 ions, and 3.8 for +3 ions) and a probability threshold of 0.001. Two distinct peptides were required for all identified proteins. Relative quantitation of identified subunits was accomplished by taking the average peak areas of the two highest peaks for a given peptide. Peak intensities were normalized against the total peak intensities.

18O Labeling—The post-digest 18O labeling procedure was performed similarly as described in the literature (17, 18). Briefly, the immobilized trypsin beads (Life Technology) were first washed by water and then added to the dried peptides of each tryptic digest (20% of the digest volume), and then again completely dried by SpeedVac. Either 18O-enriched water (95%; Sigma) or regular 18O water containing 20% acetonitrile was then each added to one of two samples and incubated overnight at 37 °C with gentle shaking. After labeling, the immobilized trypsin beads were removed using a microspin column and then further washed by acetonitrile. The 16O- or 18O-labeled samples were then combined and dried by SpeedVac. Samples were applied to the mass spectrometer as described previously. Results were the average of three independent experimental repetitions. The peaks were normalized to the median of all the ratios in the set of proteasome subunits.

RESULTS

We examined the composition, assembly, post-translational modifications, functional associating partners, and proteolytic function of the 20 S proteasomes from heart and liver (supplemental Fig. 1). The proteome biology and proteolytic functions of these two organs are summarized in supplemental Table 1. Proteome biology was studied using purified 20 S complexes (>98% purity); an approach combining multi-dimensional chromatography, and BN-PAGE was used (supplemental Fig. 2). The 20 S complexes visualized on BN-PAGE (Fig. 1A) were analyzed by MS/MS, identifying all 17 known proteasome components and the most abundant/easily detectable interacting proteins (supplemental Tables 2, 6, and 7). Our data suggests that associating proteins participated in these 20 S proteasomes in sub-stoichiometric amounts (consistent with other published reports) (19).

Proteasome Composition and Assembly—Results from BN-PAGE/LC-MS/MS show that the heart and liver 20 S proteasomes are distinct (Figs. 2–4). The chromatograms for the different trypsin-digested heart and liver 20 S samples differing in major components of the 20 S proteasomes (Fig. 1B). Three independent heart 20 S samples were remarkably similar with respect to the 20 S proteasome subunits identified and their sequence coverage (supplemental Table 2). The sequence coverage of these 17 known subunits ranged from 27.4% ± 2.9% (β1i) to 69.7% ± 2.9% (α1) for the heart, whereas those for the liver ranged from 40.9% ± 4.8% (β2i) to 64.7% ± 6.9% (β1).

Three different approaches were used to quantitatively determine the assembly of three β subunits (β1, β2, β5) and their three inducible counter parts (β1i, β2i, β5i) in the heart and liver 20 S proteasomes. First, quantification of the heart and liver 20 S proteasome subunits was carried out using the average peak area of the two highest peaks of a given peptide detected in both the heart and liver 20 S proteasomes. Label-free LC-MS/MS quantification of the 20 S proteasomes from heart and liver suggested significantly higher amounts of inducible sub-
units (β1i, β5i) in liver when compared with heart (p < 0.05, n = 3) (Fig. 2A). Second, using 16O:18O post-digestion labeling of the heart and liver proteasomes (Fig. 2B and supplemental Table 3), we also observed significantly lower inducible sub-units in the heart. Using this 16O:18O labeling the concentration of liver/heart for 1i and 5i were 3.17 ± 0.22 and 2.96 ± 0.21, respectively. Finally, a third approach was used to investigate the potentially higher levels of inducible β catalytic subunits in the liver using immunoblotting. Odyssey infrared imaging of the purified 20 S proteasomes shown in Fig. 3B allows for the quantification of the level of a given subunit.

By comparing the level of a given β catalytic subunit in the cytosol to the level in purified samples, we obtain a ratio that is directly comparable between tissues. The ratio of the total proteasome subunits (obtained from cytosolic fractions) versus trypsin cleaved heart and liver 20 S proteasomes were similar, but distinct. Some of the major peaks in both samples are labeled.
sus the proteasome subunits fully integrated into mature 20 S complexes (obtained from purified 20 S proteasomes) is referred to as the “assembly index” (Fig. 3, A and C and supplemental Table 5). These ratios, or the assembly index, compares the capacity of the heart and liver to incorporate subunits into mature proteasomes. The assembly index values for β2, β5, βi1, and β5i were greater in liver than in heart, with β2i as the exception. This provides further evidence that the liver 20 S proteasomes maintain a higher level of inducible β subunits in the liver (Fig. 3 and supplemental Table 5). Other subunits were also compared (α3, α5, and α7), and although the liver contains a higher amount of α subunits, no significant difference between the levels of α3, α5, and α7 subunits in the heart relative to the liver cytosolic fractions (supplemental Fig. 8) were observed. This suggests that there is no substantial variability in these proteasome subunit expression levels between the heart and liver.

Post-translational Modifications—Immunoblotting showed that the liver 20 S proteasomes contained higher relative amounts of phosphorylated Ser, Thr, and Tyr residues than the cardiac 20 S proteasomes (Fig. 4A), which is consistent with our previous findings (11). We have recently shown that the heart proteasome is phosphorylated on at least six residues and that phosphorylation is a key regulator of the proteasome (13, 10). Using immunoblotting, the presence of several post-translational modifications on proteasomes were investigated: ubiquitination, sumoylation, tyrosine nitrosation, glutathionylation, neddylation, and methylation. Although the proteasome fraction was found to be neddylated, no proteasome subunits were neddylated based upon the molecular mass of the neddylated protein (Fig. 5). Using mass spectrometry and immunoblotting we provide the first evidence of proteasome methylation (Fig. 4B and supplemental Fig. 5). The β6 proteasome subunit was found to be monomethylated on arginine, whereas α2 was found to be dimethylated on lysine (Fig. 4B). Immunoblotting of heart and liver proteasomes on native and two-dimensional gels using methyl-specific antibodies suggest that some proteasome sub-
units are methylated (supplemental Fig. 5). The purified 20 S proteasome was not found to be ubiquitinated, sumoylated, lysine-acetylated, or glutathiolated (supplemental Fig. 6).

**Functional Associating Partners**—Previous studies on proteasome associating partners have proven successful (20, 21). In our studies, the native 20 S complexes displayed by the BN-PAGE were analyzed by MS/MS for associating partner identification. Nine different associating partners were found to stably interact with the native 20 S proteasome complexes in both the heart and the liver including elongation factor 2, 90 kDa heat shock protein, stress-70 protein mitochondrial precursor and calpain 2 catalytic subunit (spectra shown in supplemental Fig. 4). Fig. 5 shows the MS/MS for one of the peptides used to identify NEDD8 as an associating partner for the 20 S proteasome. Several pilot experiments were carried out to assure appropriate separation of multi-
protein complexes on the BN-PAGE. Comparison of proteins identified with the 20 S complexes to those of the non-20 S complexes (those running below or above the 20 S proteasome band) enabled the elimination of false positive proteins such as glial fibrillary acidic protein.

Immunoblotting also demonstrated that NEDD8 was part of the 20 S proteasome complexes (Fig. 5). Several other well-characterized proteasome interacting partners, protein kinase A (PKA) and protein phosphatase 2A (PP2A) (10), as well as a known interacting partner, CKII, and a previously unknown interacting partner, PP1, were all observed by mass spectrometry and verified by immunoblotting (data not shown). Fig. 5 shows a spectrum from PP1 obtained from the native cardiac 20 S proteasomes, which was confirmed by immunoblotting. Similar results were also obtained for liver 20 S proteasomes (data not shown). Most of the interacting partners were found to be present in both heart and liver 20 S samples. The 11 S regulatory subunits were also examined (supplemental Fig. 9). Although no significant amount of 11 S γ was found in either cytosolic proteasomes, the 11 Sα and 11 Sβ were significantly more abundant in the liver than in heart cytosol.

Additional confidence for the verification of associating partners was demonstrated via high resolution confocal microscopy and co-immunoprecipitation. To gain insight into the cellular distribution and binding of associating partners to the proteasomes in mammalian cells, we immunostained isolated mammalian cells and imaged with confocal microscopy. PP1, CKII, NEDD8, and ZFHX4 were all confirmed to colocalize with the proteasome complexes, providing additional confidence that the associating partners were identified through BN-gel (Fig. 6). The degree of association between two proteins was measured using the PPI and CC. The PPI and CC are independent measures for validating the colocalization of PP1, CKII, NEDD8, and ZFHX4 with the proteasome and are consistent with values obtained for the colocalization of the 19 S complex (Rpt4) with the core 20 S proteasome (Fig. 6, panel 5). Associating proteins were also verified by co-immunoprecipitating the core 20 S complex from purified 20 S proteasome preparations and subsequent MS^n identification of non-proteasome proteins. Several of the associating proteins, including PP1, CKII, PKA, and PP2A were still detected to associate with 20 S proteasome complexes after co-immunoprecipitation (supplemental Table 8). Identification of associating proteins through a combination of BN-gel, immunohistochemistry, and co-immunoprecipitation provides considerable confidence that the interactions are biologically relevant.

Proteasome Activities—The three proteolytic activities (β1 caspase-like, β2 trypsic-like, β5 chymotryptic-like) of the cytosolic 20 S proteasomes were examined (Fig. 7A). Distinct patterns in proteasome function of these two organs were observed: The chymotrypsin-like proteolytic activity of the hepatic cytosolic 20 S proteasomes was significantly greater than that from cardiac cytosolic 20 S proteasomes, whereas the caspase and trypsin-like proteolytic activities of the cardiac cytosolic 20 S proteasomes were greater than that of hepatic cytosolic 20 S proteasomes.

To evaluate tissue heterogeneity and sensitivity to proteasome inhibition we examined the effect of two proteasome inhibitors on the proteolytic function of heart and liver. Our data showed that the heart had a higher susceptibility to epoxomicin than liver (Fig. 7B). Investigation of the purified heart and liver 20 S proteasomes showed that the caspase- and trypsin-like proteolytic activities were greater in the liver (Fig. 7C). The effect of proteasome inhibitors on the purified heart and liver 20 S proteasomes was also investigated (Fig. 7D). The heart 20 S proteasomes were highly sensitive to epoxomicin inhibition when compared with liver as shown in their respective β5 chymotrypsin-like activity.

PP1, which was associated with heart and liver 20 S complexes, showed distinct functional roles in the heart and liver (Fig. 8). Addition of PP1 to cardiac 20 S proteasomes significantly enhanced the β5 chymotrypsin-like activity (50% ± 2% increase when compared with heat-inactivated PP1); whereas PP1 had no detectable effect on the β5 chymotrypsin-like activity of the liver 20 S proteasomes (Fig. 8B). Inhibition of the endogenous CKII bound to 20 S proteasomes resulted in an increase in all three proteolytic activities of the liver proteasome without affecting the cardiac proteasome (Fig. 8C). Addition of CKII to liver 20 S proteasomes significantly decreased all three proteolytic activities of the liver proteasome without affecting the cardiac proteasome (Fig. 8D).

**DISCUSSION**

This investigation identified contrasting alterations of proteasome inhibition in the liver versus the heart. The sensitivities of the cytosolic cardiac 20 S proteasomes to the two proteasome inhibitors tested (epoxomicin and Z-Pro-Nle-Asp-H) were dramatically higher than in the liver. These functional consequences are concomitant with the differential proteome biology of 20 S proteasomes observed in these two organs. Despite identical genetics, 20 S complexes of these two organs differed in their molecular composition, complex assembly, post-translational modifications, functional associating partners, regulatory complexes, and proteolytic function. To our knowledge, this is the first investigation that
Fig. 6. Confocal validation of the associating partners with proteasome complexes in mammalian cells. Panel 1, representative single confocal sections of cardiomyocytes immunostained with anti-20 S proteasome α3 (A1, green), anti-PP1γ (A2, red), and the overlay of α3 and PP1γ (A3). a1–a3 are the regions in the squares at higher display magnification. A4, CC histogram. PPI of 0.87 for α3 with proximity to PP1γ, indicating a high degree of association. A5, P significance test versus CC for α3 with proximity to PP1γ; the highlighted area has <0.05. A6, PPI as a function of pixel shift. Panel 2, immunostained cells with anti-20 S proteasome α3 (B1, green), anti-CKII (B2, red), and overlay (B3). b1–b3 are regions at higher magnification. B4, CC histogram. PPI of 0.47 for α3 proximity to CKII. B5, CC for α3 with proximity to CKII; the highlighted area has p < 0.05. B6, PPI as a function of pixel shift. Panel 3, immunostained cells with anti-20 S proteasome α3 (C1, green), anti-NEDD8 (C2, red), and overlay (C3). c1–c3 are regions at higher magnification. C4, CC histogram. PPI of 0.82 for α3 proximity to NEDD8. C5, CC for α3 with proximity to NEDD8; the highlighted area has p < 0.05. C6, PPI as a function of pixel shift. Panel 4, immunostained cells with anti-20 S proteasome α3 (D1, green), anti-ZFHX4 (D2, red), and overlay (D3). d1–d3 are regions at higher magnification. D4, CC histogram. PPI of 0.64 for α3 proximity to ZFHX4. D5, CC for α3 proximity to CKII; the highlighted area has p < 0.05. D6, PPI as a function of pixel shift. Panel 5, immunostained cells with anti-core 20 S proteasome (E1, green), anti-Rpt4 19 S proteasome (E2, red), and overlay of core and Rpt4 (E3). e1–e3 are regions in the squares at higher magnification. E4, CC histogram. PPI of 0.82 for core proximity to Rpt4. E5, Psign test versus CC for core proximity to Rpt4; the highlighted area has p < 0.05. E6, PPI as a function of pixel shift.
delineates the tissue-specific heterogeneity of 20 S proteasomes in the same animal strain.

Molecular Composition and Assembly—Free proteasome subunits, partially assembled proteasomes and fully assembled proteasomes all exist simultaneously within the cell. The assembly and molecular organization of the proteasome is complex, as two sets of 7α and 7β subunits are required for 20 S proteasome assembly. The three β subunits (β1, β2, β5) can be replaced with their inducible counterparts (β1i, β2i, β5i), all of which possess catalytic activity. We have previously shown the parallel integration of all six β subunits in the 20 S proteasomes from normal adult myocardium (13, 10). In this report, using

![Proteolytic activities of the purified 20 S proteasomes from the heart and liver.](image-url)

**A**, comparison of the proteolytic activities of the 20 S proteasomes in cytosolic fractions from the heart and liver. *, *p < 0.05; n = 4. **B**, comparison of the inhibition of 20 S proteasome activities in cytosolic fractions from the heart and liver. *, *p < 0.05; n = 4. Heart and liver cytosol fractions (25 μg each) were assayed for β1, β2, and β5 activities in the presence of 100–500 mM of fluorescent substrate. *, *p < 0.05; n = 5. **C**, comparison of the proteolytic activities of the purified 20 S proteasomes from the heart and liver. *, *p < 0.05; n = 4. **D**, comparison of the inhibition of purified 20 S proteasome activities from the heart and liver.

**Fig. 7.** Proteolytic activities of the purified 20 S proteasomes from the heart and liver. A, comparison of the proteolytic activities of the 20 S proteasomes in cytosolic fractions from the heart and liver. *, *p < 0.05; n = 4. B, comparison of the inhibition of 20 S proteasome activities in cytosolic fractions from the heart and liver. *, *p < 0.05; n = 4. Heart and liver cytosol fractions (25 μg each) were assayed for β1, β2, and β5 activities in the presence of 100–500 mM of fluorescent substrate. *, *p < 0.05; n = 5. C, comparison of the proteolytic activities of the purified 20 S proteasomes from the heart and liver. *, *p < 0.05; n = 4. D, comparison of the inhibition of purified 20 S proteasome activities from the heart and liver.
three independent experimental methods (label free quantification, $^{16}$O/$^{18}$O labeling and immunoblotting), we show that the six β subunits of both cardiac and hepatic 20 S proteasomes are assembled in distinct ratios and patterns. Regulatory mechanisms for proteasome assembly in the heart and liver remain to be determined. A recent paper by Sharon et al. (22) showed that the assembly of β subunits may involve propeptide processing. The degradation of proteasome subunits is also unknown and may involve the release of previously assembled proteasome subunits into the cytosol for degradation.

Post-translational Modifications—Multiple forms of post-translational modifications of proteasomes have been reported. In this investigation and previous studies from our group (10, 11, 9) we have identified phosphorylation, N-terminal acetylation, myristoylation, and arginine and lysine methylation of proteasome subunits. These results were validated with a combined approach using mass spectrometry and immunoblotting with specific antibodies. Of interest is the detection of arginine and lysine methylation in both heart and liver 20 S subunits. This form of post-translational modifica-
tion has been implicated in other cellular processes, including protein trafficking, signal transduction, and transcriptional regulation (23). Arginine methylation is seen as a common post-translational modification and is important for protein-protein interactions. More methylated proteins are likely to be discovered in the near future as predicated by the high percentage of genes in the mammalian genome (over 1%) that encode methyltransferases (24). This is the first report of methylated proteasome subunits. The specific role of methylation on proteasome subunits is unknown but could...

Fig. 8. Characterization of the effects of calyculin A, PP1, DMAT (CKII inhibitor), or CKII on the proteolytic activities of the purified proteasomes. A, proteolytic activities of purified 20 S proteasomes 50 min after the addition of 10 nM PP1 inhibitor calyculin A. Data is average over 3–6 experiments. B, β5 proteolytic activity 50 min after 36 nM recombinant PP1 added to purified 20 S proteasomes. Other proteolytic activities showed no detectable effect. Data is average of three experiments. *, p < 0.05. C, proteolytic activities of purified 20 S proteasomes 50 min after addition of 100 nM CKII inhibitor DMAT. D, β5 proteolytic activity 60 min after 15 units of recombinant CKII were added to purified 20 S proteasomes. *, p < 0.05; n = 3–6 for all experiments.
be important for the interaction with their associating partners.

Functional Associating Partners—The proteasomes fulfill a wide range of functions in the eukaryotic cell and it is anticipated that 20 S proteasomes interact with different proteins that could modulate its activity. Any two protein associations are governed by the level of expression and degradation, the ratio of free versus assembled/associated, and the subpopulation of protein with independent function(s) from its associated/assembled form. To date, many proteasome interacting proteins are currently identified (23). These 20 S complex associated proteins may be substrates, accessory proteins, or enzymes associated with 20 S proteasome function. In this study we used blue-native gels to characterize 20 S proteasome associating partners. BN-PAGE allows for high-resolution separation of multi-protein complexes under native conditions. The final electrophoretic mobility of a multi-protein complex is determined by the amount of Coomassie dye bound and the size and shape of the complex (25).

In this study, we report two proteasome associating proteins (NEDD8 and elongation factor 2) that were found in all six 20 S proteasome preparations (three cardiac and three hepatic preparations). NEDD8, also called neddylin, is a ubiquitin-like protein (80% homology to ubiquitin) (26), that is activated by the E1 ubiquitin-activating enzyme UBA2 and then linked to an E2-like enzyme, UBC12. Like ubiquitin, NEDD8 is attached covalently to targeted proteins (neddylatation); however, the biological function of NEDD8 is unclear. NEDD8 play important roles in development and differentiation, possibly regulating the E3 ubiquitin ligase complex SCF (Skp1/Cul1/Cdc53 F box) (27), and possibly playing a role in proteolysis via the ubiquitin-proteasome system (28, 29).

Elongation factor 2 is a cytosolic protein that promotes the GTP-dependent translocation of the nascent protein chain from the A-site to the P-site of the ribosome. Its interaction with the 20 S proteasome agrees well with recent reports that Elongation factor 1 interacts with proteasomes (30). Although the interactions between elongation factor 2 and 20 S proteasomes have not been previously detected, it is likely that these translational elongation factors are involved in the degradation of co-translationally damaged proteins, linking protein synthesis and degradation pathways (31).

Other proteins that were found to associate with the proteasome in more than one 20 S proteasome sample include: protein kinase A (10), protein phosphatase 2A (10), casein kinase II, protein phosphatase 1, calpain 2, stress-70 protein mitochondrial precursor, 90 kDa heat shock protein, arginine N-methyl transferase 1, and annexin A2 (supplemental Fig. 4). The presence of casein kinase II, protein phosphatase 1, heat shock protein 90, protein kinase A, protein phosphatase 2A, elongation factor 2, and NEDD8 in both the heart and liver (Fig. 5) contrasts with the existence of zinc finger homeodomain 4 solely in the heart (supplemental Fig. 7). The inevitable loss of the more weakly bound or transient proteins during purification highlights the dynamism of the proteasome complex as well as the difficulty in developing a comprehensive map of associating partners. A growing list of 20 S proteasome associating partners, both shared and unique to particular organs, enhances the potential of functional diversity of the proteasome complexes.

Proteolytic Activity—The differences in the proteolytic activities between the heart and liver may be attributed by an organ-specific proteasome subunit composition and/or a difference in associating partners. It is also possible that because of complex heterogeneity, proteasome activators or inhibitors may differently affect proteasome activities of the heart and liver. In our study, the unique proteolytic substrate pattern exhibited by the cardiac cytosolic 20 S (higher β1 and β2 and lower β5 activities) suggests complex multifaceted mechanisms in regulating the proteasome activity in a tissue-specific manner. PP1 was associated with both the murine cardiac and hepatic 20 S proteasomes. Exogenous PP1 affected the 20 S proteasome in a tissue-specific role as it increased β5 proteolytic activity in the heart, but had no significant effect in liver. The PP1 inhibitor, calyculin A, decreased β5 activity without a demonstrable effect on β1 and β2 proteolytic activities.

Conclusion—This investigation shows that despite identical genetic input, the heart and liver manifested contrasting proteome biology in their 20 S proteasome complexes. The differences in the molecular assembly of the catalytically active β subunits as well as distinct associating partners contributed to the differential proteolytic consequences that these two organs possess. These data illustrate that structural and functional features of 20 S proteasomes are heterogeneous between tissue types. Furthermore, the cardiac proteasomes displayed much higher sensitivity to the drug epoxomicin than that of the liver. This may explain why the proteasome inhibitor Velcade showed more toxicity to cardiac cells than to normal colon cells (33). The ubiquitous presence of the 20 S proteasomes in all tissue types and the heterogeneity identified in this study recommends caution to the application of systematic administration of proteasome inhibitors in future therapeutic regiments.

* This work was supported, in whole or in part, by National Institutes of Health Grant HL R01–63901, HL R01–65431, and HL P01–80111 (to P. P.), HL BRG 088640 (to E. S.), AHA 0160144B (to A. G.), and AHA 0715004Y (to G. Y.). This work was also supported by an endowment from Theodore C. Laubisch (to P. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
REFERENCES

1. Merchionne, F., Perosa, F., and Dammacco, F. (2007) New therapies in multiple myeloma. Clin. Exp. Med. 7, 83–97
2. Voortman, J., and Giaccone, G. (2006) Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 6, 129
3. Enrico, O., Gabriele, B., Nadia, C., Sara, G., Daniele, V., Giulia, C., Antonio, S., and Mario, P. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol. 138, 396–397
4. Hachiyanifeglu, A., Tarkan, P., and Gonulle, E. (2008) Acute severe cardiac failure in myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. 88, 219–222
5. Zong, C., Gomes, A. V., Drews, O., Li, X., Young, G. W., Jones, R. C., Thyparambil, S., Wang, G. W., Qiao, X., Bardag-Gorce, F., and Ping, P. (2006) Regulation of murine cardiac 26 S proteasome: role of associating partners. Front. Biosci. 11, 282–301
6. Katz, J. E., Dlakic, M., and Clarke, S. (2003) Automated identification of multiple masses and oligomeric states of protein complexes by blue native electrophoresis. Trends Biotechnol. 21, 255–260
7. Sjö, A., Zais, D., and Kloezel, P. M. (2001) The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr. Mol. Med. 1, 665–676
8. Young, G. W., Wang, Y., and Ping, P. (2008) Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc. Med. 3, 93–98
9. Zong, C., Gomes, A. V., Drews, O., Li, X., Young, G. W., Berhane, B., Qiao, X., French, S. W., Bardag-Gorce, F., and Ping, P. (2006) Regulation of murine cardiac 20 S proteasome: role of associating partners. Circ. Res. 99, 372–380
10. Drews, O., Wildgruber, R., Zong, C., Sukup, U., Nissum, M., Gomes, A. V., and Ping, P. (2007) Mammalian proteasome substraptions with distinct molecular compositions and proteolytic activities. Mol. Cell. Proteomics 6, 2021–2031
11. Brooks, P. S., Pinner, A., Ramachandran, A., Coward, L., Barnes, S., Kim, H., and Darley-Usmar, V. M. (2002) High throughput two-dimensional blue-native electrophoresis: a tool for functional proteomics of mitochondria and signaling complexes. Proteomics 2, 969–977
12. Gomes, A. V., Zong, C., Edmondson, R. D., Li, X., Stefanii, E., Zhang, J., Jones, R. C., Thymarambil, S., Wang, G. W., Qiao, X., Bardag-Gorce, F., and Ping, P. (2006) Mapping the murine cardiac 26 S proteasome complexes. Circ. Res. 99, 362–371
13. Eghbali, M., Deva, R., Alioua, A., Minosyan, T. Y., Ruan, H., Wang, Y., Toro, L., and Stefani, E. (2005) Molecular and functional signature of heart hypertrophy during pregnancy. Circ. Res. 96, 1208–1218
14. Eghbali, M., Eghbali, M., Minosyan, T. Y., Tang, G., Toro, L., and Stefani, E. (2006) Heart estrogen receptor alpha: distinct membrane and nuclear distribution patterns and regulation by estrogen. J. Mol. Cell. Cardiol. 41, 496–510
15. Brunelle, A., Labas, V., Mailleux, A., Sharma, S., Royer, N., Vihin, J., Perret, P., Vaubourdolle, M., and Baudin, B. (2006) Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 15, 3876–3884
16. An, Y., Fu, Z., Gutierrez, P., and Fenselau, C. (2005) Solution isoelectric focusing for peptide analysis: comparative investigation of an insoluble nuclear protein fraction. J. Proteome Res. 4, 2126–2132
17. Qian, W. J., Monroe, M. E., Liu, T., Jacobs, J. M., Anderson, G. A., Shen, Y., Moore, R. J., Anderson, D. J., Zhang, R., Calvano, S. E., Lowry, S. F., Xiao, W., Moldawer, L. L., Davis, R. W., Tompkins, R. G., Camp, D. G., 2nd and Smith, R. D. (2005) Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol. Cell. Proteomics 4, 700–709
18. Coux, O., Tanaka, K., and Goldberg, A. L. (1996) Structure and functions of the 20 S and 26 S proteasomes. Annu. Rev. Biochem. 65, 801–847
19. Leggett, D. S., Hanja, J., Borodovsky, A., Crotas, B., Schmidt, M., Baker, R. T., Walter, H., Ploegh, H., and Finley, D. (2002) Multiple associated proteins regulate proteasome structure and function. Mol. Cell 10, 495–507
20. Wang, X., and Huang, L. (2008) Identifying dynamic interactors of protein complexes by quantitative mass spectrometry. Mol. Cell. Proteomics 7, 48–57
21. Sharon, M., Witt, S., Glassmacher, E., Baumeister, W., and Robinson, C. V. (2007) Mass spectrometry reveals the missing links in the assembly pathway of the bacterial 20 S proteasome. J. Biol. Chem. 282, 18448–18457
22. Bedford, M. T., and Richard, S. (2005) Arginine methylation: an emerging regulator of protein function. Mol. Cell 18, 263–272
23. Katz, J. E., Diakic, M., and Clarke, S. (2003) Automated identification of putative methyltransferases from genomic open reading frames. Mol. Cell. Proteomics 2, 525–540
24. Schagger, H., Cramer, W. A., and von Jagow, G. (1994) Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal. Biochem. 217, 220–230
25. Kamitani, T., Ito, K., Nguyen, H. P., and Yeh, E. T. (1997) Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 272, 28557–28562
26. Kawakami, T., Chiba, T., Suzuki, T., Ikai, W., Yamanaka, K., Minato, N., Suzuki, H., Shimbara, N., Hidaka, Y., Osaka, F., Omata, M., and Tanaka, K. (2001) NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 20, 4003–4012
27. Kamitani, T., Ito, K., Fukuda-Kamitani, T., and Yeh, E. T. (2001) Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J. Biol. Chem. 276, 46655–46660
28. Tateshi, K., Omata, M., Tanaka, K., and Chiba, T. (2001) The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J. Cell Biol. 155, 571–579
29. Tokumoto, T., Kondo, A., Miwa, J., Horiguchi, R., Tokumoto, M., Nagahama, Y., Okida, N., and Ishikawa, K. (2003) Regulated interaction between polypeptide chain elongation factor-1 complex with the 26 S proteasome during Xenopus oocyte maturation. BMC Biochem. 4, 6
30. Chuang, S. M., Chen, L., Lambertson, D., Anand, M., Kinzy, T. G., and Madura, K. (2005) Proteasome-mediated degradation of cotranslationally damaged proteins involves translation elongation factor 1A. Mol. Cell. Biol. 25, 403–413
31. Castano, J. G., Manillio, E., Arizti, P., and Arríbas, J. (1996) Phosphorylation of C8 and C9 subunits of the multicatalytic protease by casein kinase II and identification of the C8 phosphorylation sites by direct mutagenesis. Biochemistry 35, 3782–3789
32. Papandreou, C. N., Daliain, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S. M., Pagliaro, L., Kim, J., Adams, J., Elliott, P., Esseltine, D., Petrusch, A., Dieringer, P., Perez, G., and Logothetis, C. J. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2108–2121

Molecular & Cellular Proteomics 8.2